Not Tagged
Not Tagged
['nsclc', 'sclc']
abstract 119 #asco23 (fengying wu) phase 2a study evaluating the efficacy and safety of sutetinib in pts w/ advanced nsclc harboring uncommon egfr mutations. sutetinib demonstrated durable antitumor activity &amp; acceptable tox in pts with egfr g719x, s768i, and/or l861q mutations
A group of EGFR+ lung cancer patients who are resistant to targeted treatment. Sharing support & research news, accelerating research, improving outcomes. #lcsm